Search
-
Would You Want to Know? The Paradox of Early Cancer Detection
Read our new viewpoint and delve into the paradox of early cancer detection: how expanding screening methods – particularly multi-cancer early detection tests – while life-saving, pose considerations such as psychological impacts, false positives, and ethical dilemmas.
-
Ipsos Update – August 2025
Ageing, Healthcare, Gaming… Ipsos Update explores the latest research and thinking on key topics from Ipsos teams around the world.
-
Ipsos launches GLP-1 PersonaBot, designed to support companies’ understanding of the consumer obesity treatment market
Ipsos’ latest AI-powered innovation offers unparalleled insights into the fast-moving consumer obesity treatment market – while reinforcing Ipsos’ position at the forefront of AI applications in market research.
-
Does Everything Really Cause Cancer?
How our changing world is impacting our cells, and what it means for all of us.
-
Healthcare vs Evolution: Can GLP-1s Rewrite Our Evolutionary Story?
Our evolutionary tale began 6 million years ago, when humans were programmed to hoard calories in a world of scarcity. Today, that ancient wiring has become our greatest health risk.
-
Ipsos Answers Esomar’s Questions to help online research buyers
The primary aim of the ESOMAR's Questions is to increase transparency and raise awareness of the key issues for researchers to consider when deciding whether an online sampling approach is fit for their purpose.
-
Ipsos Update – May 2025
Misinformation, Ukraine, America … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
-
Ipsos Update – January 2025
Almanac, Predictions, Democracy … Ipsos Update explores the latest and research & thinking on key topics from Ipsos teams around the world.
-
Predicting Opportunity in Emerging Therapies
The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.